Adding atezolizumab to chemotherapy in anti-PD-L1-positive TNBC patients who have relapsed did not improve survival, as shown in the IMpassion132 trial. These patients have a poor prognosis, are typically young, and have aggressive disease resistant to standard therapies. Patients treated with capecitabine had better survival rates than those on carboplatin/gemcitabine, suggesting prior therapy may influence outcomes. Immune checkpoint inhibition did not show benefits in this trial, raising questions about its role in rapidly relapsing TNBC. Study results highlight the need for novel treatment strategies for these patients. The trial did not reveal any new safety concerns related to treatment.
Source link
No Improvement in OS With Atezolizumab in Relapsing TNBC
